Contrast-Induced Acute Kidney Injury in Patients Undergoing Carotid Artery Stenting: An Underestimated Issue

Angiology

Volumn 68, Issue 9, 2017, Pages 752-756

  Paraskevas, Kosmas I ^a   Mikhailidis, Dimitri P ^b  

^a FREEMAN HOSPITAL   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

acute kidney injury; carotid artery stenting; contrast material; contrast induced acute kidney injury

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOPHYLLINE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CREATINE KINASE; DOPAMINE; FENOLDOPAM MESILATE; PROSTAGLANDIN E1; THEOPHYLLINE; CONTRAST MEDIUM;

ACUTE KIDNEY FAILURE; ANEMIA; BRADYCARDIA; CARDIOVASCULAR DISEASE; CAROTID ARTERY OBSTRUCTION; CAROTID ARTERY STENTING; CAROTID ENDARTERECTOMY; CAROTID SINUS; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CONTRAST INDUCED NEPHROPATHY; CORONARY ANGIOGRAPHY; DEHYDRATION; ENDOVASCULAR SURGERY; ESTIMATED GLOMERULAR FILTRATION RATE; HEART INFARCTION; HOSPITAL ACQUIRED ACUTE KIDNEY FAILURE; HUMAN; HYPOALBUMINEMIA; HYPOTENSION; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; SUDDEN CARDIAC DEATH; ADVERSE DEVICE EFFECT; CHEMICALLY INDUCED; COMPLICATION; FEMALE; MALE; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; STENT; TIME FACTOR; TREATMENT OUTCOME;

ACUTE KIDNEY INJURY; CAROTID STENOSIS; CONTRAST MEDIA; ENDARTERECTOMY, CAROTID; FEMALE; HUMANS; MALE; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; STENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 85028838223     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319716668934     Document Type: Review

References (47)

1. Kernan WN, Ovbiagele B, Black HR, et al.American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014; 45 (7): 2160-2236.
2. European Stroke Organisation, Tendera M, Aboyans V, Bartelink ML, et al.ESC Committee for Practice Guidelines. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the task force on the diagnosis and treatment of peripheral artery diseases of the European Society of Cardiology (ESC). Eur Heart J. 2011; 32 (22): 2851-2906.
3. Ricotta JJ, Aburahma A, Archer E, Eskandari M, Faries P, Lal BK, Society for Vascular Surgery. Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease: executive summary. J Vasc Surg. 2011; 54 (3): e1-e31.
4. Yaganti V, Alani F, Yaganti S, Goldberg S, McCormick D,. Use of gadolinium for carotid artery angiography and stenting in patients with renal insufficiency. J Ren Care. 2009; 35 (4): 211-218.
5. Kato T, Sakai H, Tsujimoto M, Nishimura Y,. Prolonged carotid sinus reflex is a risk factor for contrast-induced nephropathy following carotid artery stenting. AJNR Am J Neuroradiol. 2011; 32 (3): 441-445.
6. Schneider LM, Roubin GS,. Minimal contrast use in carotid stenting: avoiding contrast pitfalls. J Invasive Cardiol. 2007; 19 (1): 37-38.
7. Donahue M, Visconti G, Focaccio A, et al. Acute kidney injury in patients with chronic kidney disease undergoing internal carotid artery stent implantation. JACC Cardiovasc Interv. 2015; 8 (11): 1506-1514.
8. McCullough PA, Young A, Shutze WP,. Acute kidney injury after carotid artery stenting. JACC Cardiovasc Interv. 2015; 8 (11): 1515-1517.
9. Fu M, Dai W, Ye Y, Lu Q, He W,. High dose of atorvastatin for the treatment of contrast-induced nephropathy after carotid artery stenting [published online December 29, 2015]. Am J Ther. 2015.
10. Barrett BJ, Parfrey PS,. Clinical practice. Preventing nephropathy induced by contrast medium. N Engl J Med. 2006; 354 (4): 379-386.
11. McCullough PA, Adam A, Becker CR, et al.CIN Consensus Working Panel. Risk prediction of contrast-induced nephropathy. Am J Cardiol. 2006; 98 (6A): 27K-36K.
12. McCullough PA, Stacul F, Becker CR, et al.CIN Consensus Working Panel. Contrast-induced nephropathy (CIN) Consensus working panel: executive summary. Rev Cardiovasc Med. 2006; 7 (4): 177-197.
13. Tsai TT, Patel UD, Chang TI, et al. Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR Cath-PCI registry. JACC Cardiovasc Interv. 2014; 7 (1): 1-9.
14. Davidson C, Stacul F, McCullough PA, et al.CIN Consensus Working Party. Contrast medium use. Am J Cardiol. 2006; 98 (6A): 42K-58K.
15. Turan B, Erkol A, Gul M, Findikcioglu U, Erden I,. Effect of contrast-induced nephropathy on the long-term outcome of patients with non-ST segment elevation myocardial infarction. Cardiorenal Med. 2015; 5 (2): 116-124.
16. Aurelio A, Durante A,. Contrast-induced nephropathy in percutaneous coronary interventions: pathogenesis, risk factors, outcome, prevention and treatment. Cardiology. 2014; 128 (1): 62-72.
17. Stacul F, Adam A, Becker CR, et al.CIN Consensus Working Panel. Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol. 2006; 98 (6A): 59K-77K.
18. Pappy R, Stavrakis S, Hennebry TA, Abu-Fadei MS,. Effect of statin therapy on contrast-induced nephropathy after coronary angiography: a meta-analysis. Int J Cardiol. 2011; 151 (3): 348-353.
19. Paraskevas KI, Giannoukas AD, Kotsikoris I, Mikhailidis DP,. Contrast-induced nephropathy and the vascular patient. Angiology. 2010; 61 (8): 721-723.
20. Athyros VG, Tziomalos K, Florentin M, Karagiannis A, Mikhailidis DP,. Statin loading in patients undergoing percutaneous coronary intervention for acute coronary syndrome: a new pleiotropic effect? Curr Med Res Opin. 2010; 26 (4): 839-842.
21. Briguori C, Visconti G, Focaccio A, et al.REMEDIAL II Investigators. Renal Insufficiency After Contrast Medial Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury. Circulation. 2011; 124 (11): 1260-1269.
22. Prince MR, Arnoldus C, Frisoli JK,. Nephrotoxicity of high-dose gadolinium compared with iodinated contrast. J Magn Reson Imaging. 1996; 6 (1): 162-166.
23. Schenker MP, Solomon JA, Roberts DA,. Gadolinium arteriography complicated by acute pancreatitis and acute renal failure. J Vasc Interv Radiol. 2001; 12 (3): 393.
24. Spinosa DJ, Matsumoto AH, Angle JF, et al. Safety of CO(2)- and gadodiamide-enhanced angiography for the evaluation and percutaneous treatment of renal artery stenosis in patients with chronic renal insufficiency. AJR Am J Roentgenol. 2001; 176 (5): 1305-1311.
25. Gemery J, Idelson B, Reid S, et al. Acute renal failure after arteriography with a gadolinium-based contrast agent. AJR Am J Roentgenol. 1998; 171 (5): 1277-1278.
26. Sam AD 2nd, Morasch MD, Collins J, et al. Safety of gadolinium contrast angiography in patients with chronic renal insufficiency. J Vasc Surg. 2003; 38 (2): 313-318.
27. Briguori C, Colombo A, Airoldi F, et al. Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures. Catheter Cardiovasc Interv. 2006; 67 (2): 175-180.
28. Thomsen HS, Almen T, Morcos SK, Contrast Media Safety Committee Of The European Society Of Urogenital Radiology (ESUR). Gadolinium-containing contrast media for radiographic examinations: a position paper. Eur Radiol. 2002; 12 (10): 2600-2605.
29. Schreier DZ, Weaver FA, Frankhouse J, et al. A prospective study of carbon dioxide-digital subtraction vs standard contrast arteriography in the evaluation of the renal arteries. Arch Surg. 1996; 131 (5): 503-507.
30. Dewald CL, Jensen CC, Park YH, et al. Vena cavography with CO(2) versus iodinated contrast material for inferior vena cava filter placement: a prospective evaluation. Radiology. 2000; 216 (3): 752-757.
31. Caridi JG, Stavropoulos SW, Hawkins IF Jr,. CO2 digital subtraction angiography for renal artery angioplasty in high-risk patients. AJR Am J Roentgenol. 1999; 173 (6): 1551-1556.
32. Dowling K, Kan H, Siskin G, et al. Safety of limited supplemental iodinated contrast administration in azotemic patients undergoing CO2 angiography. J Endovasc Ther. 2003; 10 (2): 312-316.
33. Goldenberg I, Matetzky S,. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. CMAJ. 2005; 172 (11): 1461-1471.
34. Attallah N, Yassine L, Musial J, Yee J, Fisher K,. The potential role of statins in contrast nephropathy. Clin Nephrol. 2004; 62 (4): 273-278.
35. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP,. Contrast-induced nephropathy: an "all or none" phenomenon? Angiology. 2015; 66 (6): 508-513.
36. Akyuz S, Yaylak B, Altay S, Kasikcioglu H, Cam N,. The role of statins in preventing contrast-induced acute kidney injury: a narrative review. Angiology. 2015; 66 (8): 701-707.
37. Mikhailidis DP, Athyros VG,. Acute kidney injury: short-term statin therapy for prevention of contrast-induced AKI. Nat Rev Nephrol. 2014; 10 (1): 8-9.
38. Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP,. Short-, mid-, and long-term benefits of peri-procedural high-intensity statin administration in patients undergoing percutaneous coronary intervention. Curr Med Res Opin. 2015; 31 (2): 191-195.
39. Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP,. Statins can improve proteinuria and glomerular filtration rate in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction? Expert Opin Pharmacother. 2015; 16 (10): 1449-1461.
40. Zhang BC, Li WM, Xu YW,. High-dose statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis. Can J Cardiol. 2011; 27 (6): 851-858.
41. Paraskevas KI, Athyros VG, Briana DD, et al. Statins exert multiple beneficial effects on patients undergoing percutaneous revascularization procedures. Curr Drug Targets. 2007; 8 (8): 942-951.
42. Paraskevas KI, Giannoukas AD, Mikhailidis DP,. Statins and contrast-induced nephropathy: issues requiring further investigation. Int J Cardiol. 2011; 151 (3): 364.
43. AbuRahma AF, Hayes JD, Deel JT, et al. Complications of diagnostic carotid/cerebral arteriography when performed by a vascular surgeon. Vasc Endovascular Surg. 2006; 40 (3): 189-195.
44. Li Q, Zhao YG, Wang Z, Jiang HP, Liu WB, Cao BF,. Effects of first high-dose atorvastatin loading in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention [published online February 23, 2016.]. Am J Ther.
45. Brosh D, Assali A, Vaknin-Assa H, et al. The ACIST power injection system reduces the amount of contrast media delivered to the patient, as well as fluoroscopy time, during diagnostic and interventional cardiac procedures. Int J Cardiovasc Intervent. 2005; 7 (4): 183-187.
46. Parlani G, De Rango P, Verzini F, et al. Safety of carotid stenting (CAS) is based on institutional training more than individual experience in large-volume centres. Eur J Vasc Endovasc Surg. 2013; 45 (5): 424-430.
47. Modrall JG, Chung J, Kirkwood ML, et al. Low rates of complications for carotid artery stenting are associated with a high clinician volume of carotid artery stenting and aortic endografting but not with a high volume of percutaneous coronary interventions. J Vasc Surg. 2014; 60 (1): 70-76.